Short-Term fasting alters cytochrome P450-Mediated drug metabolism in humans

Drug Metabolism and Disposition

Volumn 43, Issue 6, 2015, Pages 819-828

  Lammers, Laureen A ^a   Achterbergh, Roos ^a   De Vries, Emmely M ^a   Van Nierop, F Samuel ^a   Klümpen, Heinz Josef ^a   Soeters, Maarten R ^a   Boelen, Anita ^a   Romijn, Johannes A ^a   Mathôt, Ron A A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; ISOENZYME; MESSENGER RNA; METOPROLOL; MIDAZOLAM; OMEPRAZOLE; PREGNANE X RECEPTOR; TRANSCRIPTION FACTOR; WARFARIN; CYP1A2 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; HUMAN; MALE; MEAN TRANSIT TIME; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; RAT; ANIMAL; BLOOD; CLINICAL TRIAL; DIET RESTRICTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLIC CLEARANCE RATE; METABOLISM; WISTAR RAT; YOUNG ADULT;

RATTUS; RATTUS NORVEGICUS;

ADULT; ANIMALS; CAFFEINE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; FASTING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE; METOPROLOL; MIDAZOLAM; OMEPRAZOLE; RATS, WISTAR; WARFARIN; YOUNG ADULT;

EID: 84940367663     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.062299     Document Type: Article

References (35)

1. Benet LZ and Hoener BA (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115-121.
2. Bergstrand M, Hooker AC, Wallin JE, and Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143-151.
3. Buler M, Aatsinki S-M, Skoumal R, and Hakkola J (2011) Energy sensing factors PGC-1a and SIRT1 modulate PXR expression and function. Biochem Pharmacol 82:2008-2015.
4. Ding X, Lichti K, Kim I, Gonzalez FJ, and Staudinger JL (2006) Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha. J Biol Chem 281:26540-26551.
5. Ette EI (1997) Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486-495.
6. Foster KJ, Alberti KG, Hinks L, Lloyd B, Postle A, Smythe P, Turnell DC, and Walton R (1978) Blood intermediary metabolite and insulin concentrations after an overnight fast: reference ranges for adults, and interrelations. Clin Chem 24:1568-1572.
7. Hernandez JP, Mota LC, and Baldwin WS (2009) Activation of CAR and PXR by dietary, environmental and occupational chemicals alters drug metabolism, intermediary metabolism, and cell proliferation. Curr Pharmacogenomics Person Med 7:81-105.
8. Iber H, Li-Masters T, Chen Q, Yu S, and Morgan ET (2001) Regulation of hepatic cytochrome P450 2C11 via cAMP: implications for down-regulation in diabetes, fasting, and inflammation. J Pharmacol Exp Ther 297:174-180.
9. Imaoka S, Terano Y, and Funae Y (1990) Changes in the amount of cytochrome P450s in rat hepatic microsomes with starvation. Arch Biochem Biophys 278:168-178.
10. Ingelman-Sundberg M (2001) Pharmacogenetics: An opportunity for a safer and more efficient pharmacotherapy. J Intern Med 250:186-200.
11. Jonsson EN and Karlsson MO (1998) Automated covariate model building within NONMEM. Pharm Res 15:1463-1468.
12. Jonsson EN and Karlsson MO (1999) Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58: 51-64.
13. Karlsson MO and Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82: 17-20.
14. Keizer RJ, van-Benten M, Beijnen JH, Schellens JH, and Huitema AD (2011) Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 101:72-79.
15. Klein S, Sakurai Y, Romijn JA, and Carroll RM (1993) Progressive alterations in lipid and glucose metabolism during short-term fasting in young adult men. Am J Physiol 265: E801-E806.
16. Lindbom L, Pihlgren P, and Jonsson EN (2005) PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79:241-257.
17. Longo V, Ingelman-Sundberg M, Amato G, Salvetti A, and Gervasi PG (2000) Effect of starvation and chlormethiazole on cytochrome P450s of rat nasal mucosa. Biochem Pharmacol 59: 1425-1432.
18. Mandema JW, Verotta D, and Sheiner LB (1992) Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20: 511-528.
19. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894.
20. Merrell MD and Cherrington NJ (2011) Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev 43:317-334.
21. Micromedex (2014) Micromedex Solutions-Drug Monographs, Truven Health Analytics, Greenwood Village, Colorado.
22. Monostory K, Pascussi JM, Kóbori L, and Dvorak Z (2009) Hormonal regulation of CYP1A expression. Drug Metab Rev 41:547-572.
23. Murray M (2006) Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Curr Drug Metab 7:67-81.
24. O'Shea D, Davis SN, Kim RB, and Wilkinson GR (1994) Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity. Clin Pharmacol Ther 56:359-367.
25. Qu W, Rippe RA, Ma J, Scarborough P, Biagini C, Fiedorek FT, Travlos GS, Parker C, and Zeldin DC (1998) Nutritional status modulates rat liver cytochrome P450 arachidonic acid metabolism. Mol Pharmacol 54:504-513.
26. Savic RM, Jonker DM, Kerbusch T, and Karlsson MO (2007) Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34:711-726.
27. Soeters MR, Soeters PB, Schooneman MG, Houten SM, and Romijn JA (2012) Adaptive reciprocity of lipid and glucose metabolism in human short-term starvation. Am J Physiol Endocrinol Metab 303:E1397-E1407.
28. Tollet P, Enberg B, and Mode A (1990) Growth hormone (GH) regulation of cytochrome P-450IIC12, insulin-like growth factor-I (IGF-I), and GH receptor messenger RNA expression in primary rat hepatocytes: A hormonal interplay with insulin, IGF-I, and thyroid hormone. Mol Endocrinol 4:1934-1942.
29. Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, and Martin DE (1999) Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J Clin Pharmacol 39:487-494.
30. Turpault S, Brian W, Van-Horn R, Santoni A, Poitiers F, Donazzolo Y, and Boulenc X (2009) Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol 68:928-935.
31. von Haehling S and Anker SD (2010) Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 1:1-5.
32. Vorum H and Honoré B (1996) Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy. J Pharm Pharmacol 48:870-875.
33. Waxman DJ and Holloway MG (2009) Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76:215-228.
34. Wilkinson GR and Shand DG (1975) Commentary: A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
35. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2008) Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9:384-394.